TY - JOUR
T1 - Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon
AU - Lotzova, E.
AU - Savary, C. A.
AU - Quesada, J. R.
AU - Gutterman, J. U.
AU - Hersh, E. M.
PY - 1983
Y1 - 1983
N2 - Peripheral blood natural killer (NK) cell cytotoxicity of 24 cancer patients was studied prior to and after single and multiple injections of various doses of human leukocyte recombinant interferon-α clone A (IFN-αrA). The NK cell cytotoxicity of all cancer patients declined consistently 4 and 8 hours after a single injection of IFN-αrA. Twenty-four hours after the injection of IFN-αrA, NK cell cytotoxicity of patients with low NK cell phenotype (NK-LR) was significantly augmented, whereas that of patients with medium (NK-MR) or high (NK-HR) NK phenotype was depressed. After multiple injections of IFN-αrA, depression of NK cell cytotoxicity was observed in a number of NK-MR and NK-HR patients, but in some patients with NK-LR phenotype, further potentiation was observed. No direct correlation between the NK cell augmentation and serum IFN levels was detected. In in vitro studies, IFN-αrA, when added to cultures of target and effector cells of normal individuals in a dose of 103 U/ml, was efficient in augmenting NK cell cytotoxicity. NK cell cytotoxicity of cancer patients could also be augmented by the IFN-αrA preparation; however, this augmentation occurred only prior to in vivo IFN-αrA therapy. After IFN-αrA in vivo therapy, their NK cells became refractory to further in vitro IFN-αrA treatment.
AB - Peripheral blood natural killer (NK) cell cytotoxicity of 24 cancer patients was studied prior to and after single and multiple injections of various doses of human leukocyte recombinant interferon-α clone A (IFN-αrA). The NK cell cytotoxicity of all cancer patients declined consistently 4 and 8 hours after a single injection of IFN-αrA. Twenty-four hours after the injection of IFN-αrA, NK cell cytotoxicity of patients with low NK cell phenotype (NK-LR) was significantly augmented, whereas that of patients with medium (NK-MR) or high (NK-HR) NK phenotype was depressed. After multiple injections of IFN-αrA, depression of NK cell cytotoxicity was observed in a number of NK-MR and NK-HR patients, but in some patients with NK-LR phenotype, further potentiation was observed. No direct correlation between the NK cell augmentation and serum IFN levels was detected. In in vitro studies, IFN-αrA, when added to cultures of target and effector cells of normal individuals in a dose of 103 U/ml, was efficient in augmenting NK cell cytotoxicity. NK cell cytotoxicity of cancer patients could also be augmented by the IFN-αrA preparation; however, this augmentation occurred only prior to in vivo IFN-αrA therapy. After IFN-αrA in vivo therapy, their NK cells became refractory to further in vitro IFN-αrA treatment.
UR - http://www.scopus.com/inward/record.url?scp=0021020689&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021020689&partnerID=8YFLogxK
M3 - Article
C2 - 6580490
AN - SCOPUS:0021020689
SN - 0027-8874
VL - 71
SP - 903
EP - 910
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 5
ER -